The combined administration of H1R and H2R antagonists has been suggested, for example, as a prophylactic principle in anaesthesia, for the prevention of hypersensitivity reactions to drugs, e.g., in cancer chemotherapy, or for the treatment of skin diseases [10,11,12,13,14,15]. The gene discussed is HRH1; the disease is cancer.